|
CN106632337A
|
|
Idelalisib crystal, pharmaceutical composition comprising idelalisib crystal, and preparation method and application of idelalisib crystal
|
|
WO2017054755A1
|
|
Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof
|
|
CN106699743A
|
|
Pyrimidine derivative and application thereof
|
|
CN106146405A
|
|
Pharmaceutical intermediate and its production and use
|
|
CN105769752A
|
|
Method for preparing tacrolimus ointment and tacrolimus ointment
|
|
WO2016201852A1
|
|
Photoreaction device and system for preparing compound
|
|
CN106511289A
|
|
Benzenesulfonicacid lapatinib tablets and preparing method thereof
|
|
CN106483235A
|
|
The method measuring organic solvent residual content in bortezomib
|
|
CN105842350A
|
|
Method for analysis of tadalafil synthetic intermediates by high performance liquid chromatography
|
|
CN105842365A
|
|
Method for analysis of tadalafil by high performance liquid chromatography
|
|
CN106146660A
|
|
The method of isolated and purified monoclonal antibody
|
|
CN106146387A
|
|
The preparation method of ALK inhibitor
|
|
CN105983098A
|
|
Solid composition used for increasing bioavailability of insoluble antitumor drug and preparation method thereof
|
|
CN105837576A
|
|
BTK inhibitors
|
